Exact Sciences expects to post fourth quarter 2018 revenues between $142.5 million to $143.5 million, a 64 percent year-over-year increase.
Here's what you should know:
1. Approximately 292,000 Cologuard tests were completed in the quarter, a 66 percent year-over-year increase.
2. For full-year 2018 results, Exact anticipates reporting between $454 and $455 million in revenue, a 71 percent year-over-year increase. In 2018, Exact completed 934,000 Cologuard tests, a 64 percent year-over-year increase.
3. About 15,000 providers ordered Cologuard for the first time in the fourth quarter.
4. Exact has not yet prepared its financial statements for the quarter. The company plans to present its 2018 financials during its February 2019 earnings call.
6. Exact Sciences Chairman and CEO Kevin Conroy said, "2018 was a landmark year for Exact Sciences. We helped more than 930,000 people get screened for colorectal cancer, launched a partnership with Pfizer to help bring Cologuard to more patients, and scaled our operations to meet rising demand. Our team continues working hard to deliver life-changing innovations in early cancer detection. In 2019, we expect to open a new clinical lab, integrate Epic software into our operations and advance our pipeline of liquid biopsy tests."
7. Exact's stock rocketed on the positive results, closing at $75.36 Jan. 7.